MENLO PARK, Calif.,
Oct. 31, 2014 /PRNewswire/
-- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading
biotechnology company in the emerging field of regenerative
medicine, today announced that it will release third quarter
financial and operating results on Monday,
November 10, 2014 after the close of the U.S. financial
markets. The Company will host a conference call via webcast on
Monday, November 10, 2014 at
4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss third quarter
results and recent corporate developments.
For both "listen-only" participants and those participants who
wish to take part in the question-and-answer portion of the call,
the dial-in number in the U.S. is 877-407-8291. For participants
outside the U.S., the dial-in number is 201-689-8345. To access the
live webcast, go to http://www.wsw.com/webcast/cc/astb3.
A replay of the conference call will be available for seven
business days beginning about two hours after the conclusion of the
live call. The telephone dial-in number for U.S. participants is
877-660-6853. For participants outside the U.S., the replay dial-in
number is 201-612-7415. To access the replay for all callers, refer
to Conference ID 13594488. An archived webcast will also be
available for 30 days, and may be accessed at
http://www.wsw.com/webcast/cc/astb3.
About Asterias Biotherapeutics
Asterias' core technologies center on stem cells capable of
becoming all of the cell types in the human body, a property called
pluripotency. Asterias plans to develop therapies based on
pluripotent stem cells to treat diseases or injuries in a variety
of medical fields having major unmet needs and without adequate
therapies available. Asterias initial focus is on two clinical
stage programs including oligodendrocyte progenitor cells
(AST-OPC1) for spinal cord injuries and antigen-presenting
allogeneic dendritic cells (AST-VAC2) for lung cancer.
In October 2013, Asterias acquired
the cell therapy assets of Geron Corporation. These assets included
INDs for the clinical stage AST-OPC1 and AST-VAC1 programs, banks
of cGMP-manufactured AST-OPC1 drug product, cGMP master and working
cell banks of human embryonic stem cells, over 400 patents and
patent applications filed worldwide including broad issued claims
to fundamental platform technologies for the scalable growth of
pluripotent stem cells and compositions of matter for several
hESC-derived therapeutic cell types, research cell banks,
customized reagents and equipment, and various assets relating to
the AST-VAC2 program and preclinical programs in cardiology, and
orthopedics.
Asterias is a majority-owned subsidiary of BioTime, Inc., (NYSE
MKT: BTX), a biotechnology company engaged in research and product
development in the field of regenerative medicine. Additional
information about Asterias can be found at
www.asteriasbiotherapeutics.com.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Asterias, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Asterias,
particularly those mentioned in the cautionary statements found in
Asterias' filings with the Securities and Exchange Commission.
Asterias disclaims any intent or obligation to update these
forward-looking statements.
SOURCE Asterias Biotherapeutics, Inc.